EGFR and neoplasm: This potential probiotic has considerable “protective” anti-cancer properties comparable to the already in use drugs cetuximab and trastuzumab and is able to concomitantly down regulate EGFR, HER-2 and PTGS-2 (COX-2) onco-markers and significantly ameliorate disease activity index, restore colon length, inhibit the increase in tumor incidence and prevent the progress of tumors to higher stages and grades.